Scienture Secures Third Patent for ARBLI™, Extending Market Exclusivity to 2041
Event summary
- Scienture Holdings, Inc. received its third patent for ARBLI™ (losartan potassium) oral suspension, extending market exclusivity through October 2041.
- ARBLI™ is the first and only FDA-approved ready-to-use oral liquid formulation of losartan, addressing a $241M U.S. market with 72M prescriptions annually.
- The new patent (U.S. Patent No. 12,605,365) strengthens Scienture's intellectual property portfolio, reinforcing ARBLI™'s position as a market leader in liquid losartan formulations.
- ARBLI™ eliminates the need for compounding, offering a consistent, convenient, and scalable solution for patients with difficulty swallowing tablets.
The big picture
Scienture's third patent for ARBLI™ solidifies its long-term market exclusivity, addressing a significant unmet need in the losartan market. The patent extension to 2041 provides a strategic advantage, reinforcing ARBLI™'s position as the go-to solution for patients requiring liquid dosing options. This move aligns with broader industry trends towards specialized pharmaceutical products that enhance patient compliance and access.
What we're watching
- Market Penetration
- How Scienture will leverage the extended patent protection to accelerate ARBLI™'s market adoption and capture share in the losartan market.
- Commercial Strategy
- Whether Scienture can sustain the growth momentum for ARBLI™ through increased physician awareness and expanded formulary access.
- Competitive Dynamics
- The pace at which competitors may develop alternative liquid losartan formulations, potentially challenging ARBLI™'s market dominance.
Related topics